Sample digest
What lands in your inbox every Monday
Below is an example weekly digest. Your live version is personalized to your tracked therapeutic areas, jurisdictions, and watchlists — this preview shows the structure and depth of analysis on every patent.
PharmaCliff — Week of March 18, 2026 — 3 patents flagged in your areas
Tracked areas: Cardiovascular, Oncology, Respiratory · Jurisdictions: US, EP, IN, JP, KR
Compositions and methods for treating chronic heart failure with neprilysin inhibitors
- First generic entry window opens in 84 days
- 2 ANDAs already filed in Orange Book (Aurobindo, Lupin) — Para IV certifications recorded
- Cluster signal: 4 family members across US/EP converging on similar expiry window
PharmaCliff analysis
Direct match to your cardiovascular focus. Sacubitril/valsartan formulation patent — commercial opportunity for follow-on filers is large but narrowing as the Para IV window approaches. Recommend prioritizing FTO review and supplier sourcing now; first-to-file 180-day exclusivity is unlikely (already claimed).
Source: FDA Orange Book, USPTO PAIR, EPO INPADOC · Updated Mar 18, 2026
Antibody-drug conjugates targeting HER2-positive metastatic breast cancer
- 6-member INPADOC family across US/EP/JP/KR — cliff converges across 4 major jurisdictions within 14 months
- No biosimilar approvals yet at FDA or EMA
- Two BLA pre-submissions referenced in public FDA correspondence
PharmaCliff analysis
Trastuzumab-emtansine composition claim. Biosimilar window opens 2026 H2 — significant manufacturing lead-time required, so commit-or-pass decision should happen this quarter. Family convergence makes this a multi-market opportunity, not just US.
Source: EPO INPADOC, FDA BLA register, EMA biosimilar pipeline · Updated Mar 18, 2026
Methods of using GLP-1 receptor agonists for cardiovascular risk reduction
- Semaglutide CV outcomes method claim — narrower than the composition patent
- 1 ANDA filed (Mylan, Q4 2025) — slow ANDA volume suggests weaker generic interest
- Adjacent method claim (US 9,234,567) may extend effective protection — FTO review recommended
PharmaCliff analysis
Method-of-use claim only — less defensible than composition, but Novo Nordisk has a layered claim strategy that often outlasts the headline expiry. Monitor adjacent filings before committing R&D. Probably not a Day-1 launch candidate; better suited to a 2027 portfolio entry.
Source: FDA Orange Book, USPTO PAIR · Updated Mar 18, 2026
Coming next 12 weeks (preview)
How PharmaCliff scores each patent
- Signal extraction. Pulls structured data from FDA Orange Book (ANDA filings, exclusivity windows), USPTO PAIR (legal status, Para IV certifications), and EPO INPADOC (multi-jurisdiction family).
- CPC pre-filter. Only patents matching CPC anchors for your tracked therapeutic areas reach the AI step — no LLM noise on irrelevant filings.
- AI-written analysis. Each entry gets a plain-English verdict (HIGH/MEDIUM/LOW) with the specific signals behind it. You see the reasoning, not a black-box score.
- Sources cited inline. Every signal links back to the underlying record so your team can verify before acting.
Next step
Founding-tier seats are limited to 50 and reserved manually during the beta — Stripe checkout opens shortly. To reserve a seat now, email hello@pharmacliff.com.
€39/mo lifetime · capped at 50 seats · price locks for the life of your subscription.